IRIS
LADETTO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.855
NA - Nord America 3.953
AS - Asia 3.741
SA - Sud America 845
AF - Africa 145
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 5
Totale 13.554
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.808
RU - Federazione Russa 1.869
SG - Singapore 1.476
IE - Irlanda 1.352
HK - Hong Kong 706
BR - Brasile 656
CN - Cina 602
VN - Vietnam 478
SE - Svezia 319
IT - Italia 287
DE - Germania 278
UA - Ucraina 248
FR - Francia 224
BD - Bangladesh 107
IN - India 90
GB - Regno Unito 80
AR - Argentina 67
CA - Canada 65
FI - Finlandia 65
BJ - Benin 59
MX - Messico 53
ID - Indonesia 52
EC - Ecuador 43
KR - Corea 37
JP - Giappone 33
IQ - Iraq 32
NL - Olanda 28
ZA - Sudafrica 27
PL - Polonia 23
CO - Colombia 20
AT - Austria 19
TR - Turchia 19
CL - Cile 16
PK - Pakistan 15
VE - Venezuela 15
EG - Egitto 14
UZ - Uzbekistan 13
SA - Arabia Saudita 12
ES - Italia 11
LT - Lituania 11
PE - Perù 11
PY - Paraguay 11
MA - Marocco 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
IR - Iran 9
KE - Kenya 9
DZ - Algeria 7
JM - Giamaica 7
EU - Europa 6
PH - Filippine 6
AU - Australia 5
CR - Costa Rica 5
BO - Bolivia 4
GR - Grecia 4
KZ - Kazakistan 4
MY - Malesia 4
PT - Portogallo 4
AZ - Azerbaigian 3
BE - Belgio 3
DO - Repubblica Dominicana 3
JO - Giordania 3
LB - Libano 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
SV - El Salvador 3
TH - Thailandia 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
EE - Estonia 2
HN - Honduras 2
HR - Croazia 2
KW - Kuwait 2
NP - Nepal 2
PA - Panama 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
ZM - Zambia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
DK - Danimarca 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
Totale 13.541
Salva come PNG Salva come JPEG
Città #
Dublin 1.348
Hong Kong 704
San Jose 535
Singapore 398
Ashburn 315
Jacksonville 299
Moscow 255
Wilmington 196
Lauterbourg 192
Princeton 175
Lawrence 174
Ho Chi Minh City 163
San Mateo 145
Chandler 130
Council Bluffs 130
Los Angeles 130
Beijing 119
Hanoi 95
Dearborn 84
New York 81
Buffalo 79
Dallas 73
Cotonou 59
São Paulo 58
Redondo Beach 48
Santa Clara 42
Orem 33
Seoul 33
Frankfurt am Main 29
Houston 29
Novara 29
Boardman 28
Piemonte 28
Tokyo 28
Turin 27
Bremen 26
Rio de Janeiro 25
Chennai 24
Falkenstein 24
St Louis 24
Ann Arbor 23
Helsinki 23
Tianjin 23
Toronto 22
Warsaw 22
Haiphong 21
Da Nang 19
Fairfield 19
Guangzhou 19
Montreal 19
Atlanta 18
Brooklyn 18
Denver 18
Mexico City 18
Milan 18
Nuremberg 17
Amsterdam 16
Brasília 16
London 16
Quito 16
Columbus 15
Norwalk 15
Andover 14
Des Moines 14
San Francisco 14
Stockholm 14
Chicago 13
Johannesburg 13
Poplar 13
Tashkent 13
Woodbridge 13
Baghdad 12
Mumbai 12
Ninh Bình 12
Rome 12
Thái Bình 12
Vienna 12
Shanghai 11
Boston 10
Curitiba 10
Phoenix 10
Biên Hòa 9
Brno 9
Guayaquil 9
Hangzhou 9
Munich 9
Porto Alegre 9
Querétaro 9
Belo Horizonte 8
Hefei 8
Jakarta 8
Manchester 8
Mülheim 8
Salvador 8
Seattle 8
Shenzhen 8
Asunción 7
Buenos Aires 7
Campinas 7
Cape Town 7
Totale 7.214
Salva come PNG Salva come JPEG
Nome #
STAble: A novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow 135
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 134
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 133
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 130
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 130
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 129
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 123
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes 120
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia 119
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 117
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 116
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 111
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 109
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 108
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 106
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 103
Genetic and phenotypic attributes of splenic marginal zone lymphoma 103
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies 102
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 97
COMPARISON OF TWO REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION PERFORMANCE 96
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 96
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 95
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 95
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment 95
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF PROGRESSION AND OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA 95
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 94
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice 93
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia 93
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 93
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib 89
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 87
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial 86
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 86
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 86
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 85
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma 85
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 84
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 82
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 79
CAR-T therapy: the role of the hematopoietic stem cell processing laboratory 78
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors 78
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 78
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 77
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 76
The black swan: a case of central nervous system graft-versus-host disease 76
Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 76
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 76
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 76
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes 75
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 75
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients 74
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 74
Pharmacotherapy considerations for patients who develop acute kidney injury during cancer therapy 73
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial 73
Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case 73
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 71
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 71
Droplet Digital PCR Assay for MYD88L265P 71
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 70
Controversies in the treatment of follicular lymphoma 70
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 69
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 69
DEL(13q14) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13q DELETION ALONE OR NORMAL KARYOTYPE 69
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 69
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial 69
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 68
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma 67
LENALIDOMIDE PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB IS SAFE AND EFFECTIVE IN UNTREATED, ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I STUDY BY THE FONDAZIONE ITALIANA LINFOMI 67
LOW CD49d AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME 67
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias 67
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT 67
Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units 66
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy 66
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 66
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests 66
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma 65
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network 65
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 65
The adulthood of MRD detection in MCL 64
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells 63
TWO MAIN GENETIC PATHWAYS LEAD TO THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME 63
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial 62
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 62
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity 62
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells 62
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma 62
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial 61
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 61
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 61
ESMO consensus conference on Malignant lymphoma: Management of ‘ultra-high-risk’ patients 61
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma 60
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft 60
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020 59
Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study 59
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 59
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 59
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma 59
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 59
Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 59
The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma 59
Totale 8.123
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.885
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.885
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 0 0 0 9
2021/2022794 4 20 143 55 47 0 16 16 81 13 172 227
2022/20231.966 179 37 76 18 69 123 41 93 1.251 8 50 21
2023/2024706 17 29 30 12 160 5 176 10 6 16 38 207
2024/20252.233 45 7 41 14 22 217 152 119 805 391 65 355
2025/20266.984 165 212 578 1.113 537 493 1.007 1.127 528 617 407 200
Totale 13.840